Abivax S.A. ABVX
Annual
Quarterly
No annual revenue total was found in Abivax S.A.'s SEC filings.
Abivax S.A. (ABVX) files with the SEC under industry code 2834, Pharmaceutical Preparations.
Revenue
—
Net income
—
Operating cash flow
—
Free cash flow
—
EPS
—
Dividend per share
None
Shares outstanding
78.54M
+24.0% vs prior year
Net cash
—
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ABVX (Nasdaq), AAVXF (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- France
- Headquarters
- Paris
- SEC filer status
- Accelerated filer, Emerging growth company
- SEC CIK
- 1956827
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 6-K | Current report (foreign issuer) | Sep 21, 2026 | Jun 30, 2026 |
| 6-K | Current report (foreign issuer) | Jul 2, 2026 | Jul 2, 2026 |
| 6-K | Current report (foreign issuer) | Jun 29, 2026 | Jun 29, 2026 |
| 6-K | Current report (foreign issuer) | Jun 2, 2026 | Jun 1, 2026 |
| 6-K | Current report (foreign issuer) | May 22, 2026 | Mar 31, 2026 |
| 6-K | Current report (foreign issuer) | May 20, 2026 | May 20, 2026 |
All 105 Abivax S.A. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.